221 related articles for article (PubMed ID: 32683564)
21. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
22. Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?
Hoskoppal D; Reisenbichler ES
Hum Pathol; 2018 Dec; 82():158-162. PubMed ID: 30067949
[TBL] [Abstract][Full Text] [Related]
23. MRI findings of cancers preoperatively diagnosed as pure DCIS at core needle biopsy.
Huang YT; Cheung YC; Lo YF; Ueng SH; Kuo WL; Chen SC
Acta Radiol; 2011 Dec; 52(10):1064-8. PubMed ID: 21969708
[TBL] [Abstract][Full Text] [Related]
24. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
25. Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature.
Dória MT; Maesaka JY; Soares de Azevedo Neto R; de Barros N; Baracat EC; Filassi JR
Clin Breast Cancer; 2018 Oct; 18(5):e805-e812. PubMed ID: 29798815
[TBL] [Abstract][Full Text] [Related]
26. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
27. Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?
Shi B; Grimm LJ; Mazurowski MA; Baker JA; Marks JR; King LM; Maley CC; Hwang ES; Lo JY
Acad Radiol; 2017 Sep; 24(9):1139-1147. PubMed ID: 28506510
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
29. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.
Huo L; Sneige N; Hunt KK; Albarracin CT; Lopez A; Resetkova E
Cancer; 2006 Oct; 107(8):1760-8. PubMed ID: 16977650
[TBL] [Abstract][Full Text] [Related]
30. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.
Lee JS; Fackler MJ; Teo WW; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Argani P; Sukumar S
Cancer Biol Ther; 2008 Sep; 7(9):1398-406. PubMed ID: 18769130
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
32. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.
Genco IS; Ozgultekin B; Hosseini H; Hackman K; Ferreira L; Santagada E; Wahl S; Hajiyeva S
Pathol Res Pract; 2020 Dec; 216(12):153283. PubMed ID: 33197837
[TBL] [Abstract][Full Text] [Related]
33. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
[TBL] [Abstract][Full Text] [Related]
34. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
35. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
37. US-guided 14G core needle biopsy: comparison between underestimated and correctly diagnosed breast cancers.
Kim H; Youk JH; Kim JA; Gweon HM; Jung WH; Son EJ
Asian Pac J Cancer Prev; 2014; 15(7):3179-83. PubMed ID: 24815467
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
[TBL] [Abstract][Full Text] [Related]
39. Predicting underestimation of ductal carcinoma in situ: a comparison between radiomics and conventional approaches.
Li J; Song Y; Xu S; Wang J; Huang H; Ma W; Jiang X; Wu Y; Cai H; Li L
Int J Comput Assist Radiol Surg; 2019 Apr; 14(4):709-721. PubMed ID: 30569330
[TBL] [Abstract][Full Text] [Related]
40. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
